
Agreement - November 15, 2013
Orion licenses the levosimendan injection rights in the USA and Canada to Phyxius
Orion Corporation and Phyxius Pharma have entered into a licensing agreement for levosimendan injection. According to the agreement Phyxius Pharma will develop and commercialize levosimendan in the USA and Canada for a new cardiovascular indication, prevention of Low Cardiac Output Syndrome (LCOS) in cardiac surgery patients. LCOS is a common complication in patients undergoing cardiac […]